Biotechnology →
- 30 Mar 2021
- Working Paper Summaries
Kidney Exchange: An Operations Perspective
Kidney exchange has become a standard form of transplantation in the United States and a few other countries in part because of exchange process improvements. However, much more needs to be done: There are still many more patients in need of transplants than can be saved.
- 01 Sep 2020
- Cold Call Podcast
How to Launch a New Biosciences Product: Start Small or Dive in?
C16 Biosciences wants to replace palm oil, a major contributor to deforestation, with a lab-grown substitute. But CEO Shara Ticku faces a tough decision in bringing the product to market. Jeff Bussgang discusses his case study. Open for comment; 0 Comments.
- 10 Aug 2020
- Research & Ideas
COVID's Surprising Toll on Careers of Women Scientists
Women scientists and those with young children are paying a steep career price in the pandemic, according to new research by Karim Lakhani, Kyle Myers, and colleagues. Open for comment; 0 Comments.
- 18 Sep 2019
- Working Paper Summaries
Female Inventors and Inventions
Does the gender of inventors make a difference for who benefits from their inventions? Analysis of all U.S. biomedical patents issued between 1976 and 2010 shows that research teams with women were more likely to produce patents addressing women’s health conditions, especially when female researchers led the teams. This link suggests that the dearth of women inventors might also result in fewer female-focused inventions.
- 28 Feb 2019
- Cold Call Podcast
Pursuing Precision Medicine at Intermountain Healthcare
What happens when Intermountain Healthcare invests resources in an innovative precision medicine unit to provide life-extending, genetically targeted therapies to late-stage cancer patients? Professors Richard Hamermesh and Kathy Giusti discuss the case and its connections to their work with the Kraft Precision Medicine Accelerator. Open for comment; 0 Comments.
- 26 Jul 2016
- Working Paper Summaries
The Impact of the Entry of Biosimilars: Evidence from Europe
Biosimilars are large-molecule drugs that, while not an exact copy of already-approved large-molecule drugs, have been shown to be therapeutically equivalent. Much like generic drugs, which become available when a small-molecule drug goes off patent, biosimilars are lower in cost than their reference products and present an opportunity for savings when large-molecule drugs’ patents expire. Biosimilars have been available in the United States only since 2015 but have been regulated, approved, and sold in Europe for over a decade. This paper examines the European experience to help inform policy design and institutional choices for the United States. Topics covered include the entry of distributors and unique products; predictors of average product prices following biosimilar competition; and penetration of biosimilars as a share of total sales.
- 11 Nov 2015
- Working Paper Summaries
Public R&D Investments and Private-sector Patenting: Evidence from NIH Funding Rules
By tracing the often-circuitous path from National Institutes of Health (NIH) funding to patented innovations, this research examines the effects of public science on private sector innovation in the life sciences.
- 21 Apr 2014
- Research & Ideas
Bio-Piracy: When Western Firms Usurp Eastern Medicine
Raj Choudhury and Tarun Khanna examine the history of herbal patent applications, challenging a stereotype that characterizes Western firms as innovators and emerging markets as imitators. Open for comment; 0 Comments.
- 05 Dec 2013
- Op-Ed
Encourage Breakthrough Health Care by Competing on Products Rather Than Patents
For too long, the science behind breakthrough therapeutics has been locked behind patents held by universities. Richard Hamermesh proposes the market compete on solutions rather than intellectual property rights. Closed for comment; 0 Comments.
- 09 Apr 2012
- Research & Ideas
Who Sways the USDA on GMO Approvals?
Government agencies can be "captured" by the very companies or industries they regulate. Looking at how genetically altered food products are approved, Assistant Professor Shon R. Hiatt finds unexpected influencers on the US Department of Agriculture. Key concepts include: "Regulatory capture" describes the phenomenon whereby regulatory agencies tasked with serving the public instead end up advancing the interests of the companies they regulate. Traditional theories of capture such as lobbying and campaign contributions had little effect on whether the US Department of Agriculture approved any particular genetically altered agriculture product. What did seem to affect the approval process was the influence of third-party groups such as associations and even related regulatory agencies. Open for comment; 0 Comments.
- 05 Jan 2011
- Op-Ed
Funding Unpredictability Around Stem-Cell Research Inflicts Heavy Cost on Scientific Progress
Funding unpredictability in human embryonic stem-cell research inflicts a heavy cost on all scientific progress, says professor William Sahlman. Open for comment; 0 Comments.
- 15 Sep 2010
- Working Paper Summaries
From Bench to Board: Gender Differences in University Scientists’ Participation in Commercial Science
Does gender affect whether a university scientist will be invited to work with for-profit companies? Indeed it does. A new paper finds that male professors receive more opportunities than their female counterparts to join scientific advisory boards and start new companies. Research, focusing on the biotechnology field, was conducted by Haas School of Business professor Waverly W. Ding, MIT Sloan professor Fiona Murray, and HBS professor Toby E. Stuart. Key concepts include: University-employed scientists helped to found at least half of the publicly traded biotech firms in existence today. Women scientists receive far fewer invitations than men to join scientific advisory boards, and so male scientists are more than twice as likely as female scientists to become formal board advisors. When female scientists do receive invitations to join boards, they generally come from small start-ups with limited financial backing, rather than from high-profile companies backed by high-status venture capitalists. The corporate gender gap increases among scientists employed at elite universities or academic departments. However, the gender gap decreases at schools with formal technology transfer offices, indicating that institutional support can help women overcome obstacles to entry into commercial science. Closed for comment; 0 Comments.
- 09 Sep 2010
- Working Paper Summaries
Boundary Spanning in a For-Profit Research Lab: An Exploration of the Interface Between Commerce and Academe
In science-based industries, innovation requires bridging the boundary between universities and companies. As entrepreneurial faculty venture into the world of commerce by building relationships and reputations in industry, company researchers and dealmakers seek access to the distributed knowledge base that resides within the community of scholars. But what happens within organizations when scientists venture deeply into the world of academe? In this look at one influential life sciences company, Christopher C. Liu of the Rotman School of Management and Toby E. Stuart of Harvard Business School find important connections between publishing, the allocation of rewards within the company, and the structure of the communication network inside and beyond the borders of the organization. Key concepts include: Researchers who publish successfully were rewarded by the company with an increased bonus. These publishers not only received more remuneration, they also attracted more of their managers' attention than did non-publishers. Publishers had significantly more correspondents in universities than do non-publishers. E-mail data provide direct evidence that publishing correlated with a company's access to the informal networks of the broader scientific community. However, publishers made a potentially negative tradeoff: As they spanned boundaries with the academic community, their importance in their company's communication network was weakened. Employees who are the best networked beyond the firm's boundaries should be precisely those people who would ideally occupy central positions within the firm. Yet in the study, these same individuals seemed to shift the locus of their interaction toward communities away from the firm. Closed for comment; 0 Comments.
- 27 Aug 2008
- Research & Ideas
Creating Leaders for Science-Based Businesses
The unique challenges of managing and leading science-based businesses—certain to be a driver of this century's new economy—demand new management paradigms. At Harvard Business School, the opportunities start just across the street. From HBS Alumni Bulletin. Key concepts include: Despite the hundreds of billions of dollars invested in biotech in recent decades, most biotech companies do not turn a profit. Science-based companies require a different kind of leadership, which HBS intends to develop through research, analysis and teaching. Harvard's new science complex being built across from Harvard Business School presents many opportunities for cross-fertilization. Closed for comment; 0 Comments.
- 24 Sep 2007
- Research & Ideas
The FDA: What Will the Next 100 Years Bring?
With the possible exception of the Internal Revenue Service, no other governmental agency touches the lives of more Americans than the U.S. Food and Drug Administration, which ensures the safety of $1.5 trillion worth of consumer goods and medicines. Harvard Business School professor Arthur A. Daemmrich discusses the impact and challenges of the agency and his new book, Perspectives on Risk and Regulation: The FDA at 100. Closed for comment; 0 Comments.
- 30 May 2007
- Research & Ideas
Health Care Under a Research Microscope
Perhaps no industry has caught the research attention of Harvard Business School faculty as much as health care. Researchers are investigating business-focused solutions on everything from improving team work among surgical teams to developing market motivations that increase the use of water purification in poor villages. Key concepts include: The $2 trillion American health care system has grown bloated and overly expensive, and it delivers poor service to many patients. Harvard Business School faculty are looking at the system through a business management perspective to recommend changes in almost all aspects of health care research and delivery. Around the world, HBS researchers are studying ways to improve medical services to the poor using techniques that include everything from motivational marketing to microfinance. Closed for comment; 0 Comments.
- 13 Nov 2006
- Research & Ideas
Science Business: What Happened to Biotech?
After thirty years the numbers are in on the biotech business—and it's not what we expected. The industry in aggregate has lost money. R&D performance has not radically improved. The problem? In a new book, Professor Gary Pisano points to systemic flaws as well as unhealthy tensions between science and business. Key concepts include: The biotech industry has underperformed expectations, caught in the conflicting objectives and requirements between science and business. The industry needs to realign business models, organizational structures, and financing arrangements so they will place greater emphasis on long-term learning over short-term monetization of intellectual property. A lesson to managers: Break away from a strategy of doing many narrow deals and focus on fewer but deeper relationships. Closed for comment; 0 Comments.
- 13 Feb 2006
- Research & Ideas
The Hidden Market for Babies
Surrogates. Fertility clinics. Egg donors. Adoption. It's time to recognize (and perhaps regulate) the huge market being created by reproductive technologies, says HBS professor Debora L. Spar. She discusses her new book, The Baby Business. Closed for comment; 0 Comments.
- 08 Dec 2003
- Research & Ideas
Why Europe Lags in Pharmaceuticals and Biotech
Governmental, cultural and academic differences are hurting Europe’s chances of gaining on the U.S. Can anything be done? Closed for comment; 0 Comments.
The Trial of Elizabeth Holmes: Visionary, Criminal, or Both?
Eugene Soltes explains why the fraud case against the Theranos cofounder isn't as simple as it seems, and why a conviction probably wouldn't deter unethical behavior from others. Open for comment; 0 Comments.